November 23, 2016 | Infographic, emerging markets, interactive
An overview of the six most-commonly researched, largest pharma markets in Latin America
The LATAM region’s largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With pharmaceutical sales of more than $64bn, it is an attractive market for pharma, however it is also one in which each market differs in terms of opportunities and challenges. Our interactive infographic provides an overview of the six most-commonly researched, largest pharma markets in Latin America.
http://www.researchpartnership.com/news/2016/08/interactive-infographic-latam/
This content was provided by Inizio
Latest Content from Inizio
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,…
Pegasus, the UK’s leading independent health communications consultancy, added three awards to its 2014 portfolio at last weekend’s AMEC International Summit 2014 in Amsterdam
Brighton consultancy adds top honour to its award wins
Brighton-based independent healthcare specialist looks to add award to growing list of accolades
Top UK Healthcare Communications Consultancy Moves to Brighton
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation…
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
